News|Articles|August 7, 2026

Supplements And Featured Publications

  • Long-Term Repigmentation Outcomes With OPZELURA® (Ruxolitinib) Cream 1.5% in Nonsegmental Vitiligo Regardless of Baseline Disease Activity

Long-Term Repigmentation Outcomes With OPZELURA® (Ruxolitinib) Cream 1.5% in Nonsegmental Vitiligo Regardless of Baseline Disease Activity

Sponsored by Incyte.


Latest CME